Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

S. Ederhy; A. Hollebecque; N. Haddour; C. Massard; G. Fleury; C. Ferte; S. Adavane; B. Besse; F. Boccara; J. C. Soria; A. Cohen

doi:10.1016/j.rmr.2013.09.021

Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

Translated title of the contribution: Management of the cardiovascular complications of treatment in thoracic oncology

S. Ederhy, A. Hollebecque, N. Haddour, C. Massard, G. Fleury, C. Ferte, S. Adavane, B. Besse, F. Boccara, J. C. Soria, A. Cohen

Research output: Contribution to journal › Article › peer-review

Abstract

The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

Translated title of the contribution	Management of the cardiovascular complications of treatment in thoracic oncology
Original language	French
Article number	810
Pages (from-to)	173-180
Number of pages	8
Journal	Revue des Maladies Respiratoires
Volume	31
Issue number	2
DOIs	https://doi.org/10.1016/j.rmr.2013.09.021
Publication status	Published - 1 Jan 2014

Access to Document

10.1016/j.rmr.2013.09.021

Cite this

@article{d824c8c07c4149d2a90d1cfe1e2ea29b,

title = "Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique",

abstract = "The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.",

keywords = "Anti-angiogenic, Arterialhypertension, Chemotherapy, Congestive heartfailure",

author = "S. Ederhy and A. Hollebecque and N. Haddour and C. Massard and G. Fleury and C. Ferte and S. Adavane and B. Besse and F. Boccara and Soria, {J. C.} and A. Cohen",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.rmr.2013.09.021",

language = "Fran{\c c}ais",

volume = "31",

pages = "173--180",

journal = "Revue des Maladies Respiratoires",

issn = "0761-8425",

number = "2",

}

TY - JOUR

T1 - Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

AU - Ederhy, S.

AU - Hollebecque, A.

AU - Haddour, N.

AU - Massard, C.

AU - Fleury, G.

AU - Ferte, C.

AU - Adavane, S.

AU - Besse, B.

AU - Boccara, F.

AU - Soria, J. C.

AU - Cohen, A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

AB - The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

KW - Anti-angiogenic

KW - Arterialhypertension

KW - Chemotherapy

KW - Congestive heartfailure

UR - http://www.scopus.com/inward/record.url?scp=84900809195&partnerID=8YFLogxK

U2 - 10.1016/j.rmr.2013.09.021

DO - 10.1016/j.rmr.2013.09.021

M3 - Article

C2 - 24602684

AN - SCOPUS:84900809195

SN - 0761-8425

VL - 31

SP - 173

EP - 180

JO - Revue des Maladies Respiratoires

JF - Revue des Maladies Respiratoires

IS - 2

M1 - 810

ER -

Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

Abstract

Access to Document

Other files and links

Cite this